Background. An effective vaccine is urgently needed against the H7N9 avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets.
Since its emergence in China, the avian H7N9 influenza virus continues to spread and cause human infections with a high case fatality rate [1, 2] . Infection control is difficult because the virus causes only mild infections in poultry and is now widespread in China [3] . An effective vaccine is therefore needed to protect against infection and to limit virus spread. However, development of an effective avian influenza vaccine has been hampered by the poor immunogenicity reported in various human clinical trials for candidate H5N1, H7N7, and H7N1 vaccines [4] [5] [6] [7] . Furthermore, elderly persons, who have been disproportionately affected by H7N9 [2] , respond poorly to influenza vaccines [8] . One strategy to improve the immunogenicity of vaccines is with the use of adjuvants. Particularly successful adjuvants are the squalene oilin-water emulsion adjuvants, MF59 (Novartis Vaccines) and AS03 (GlaxoSmithKline).
In the current study, we evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine, administered with or without the MF59 or AS03 adjuvants, in the ferret model. We also evaluated the composition of the H7N9 vaccine in a series of in vitro assays, as done previously [9] . We undertook this study to mirror that of the recently completed National Institute of Allergy and Infectious Diseases-sponsored human phase II clinical trials (http://clinicaltrials.gov; NCT 01942265 and 01938742), with the aim that our data will complement the findings of the human study.
MATERIALS AND METHODS

Vaccines and Adjuvants
The H7N9 vaccine candidate, MF59 and AS03-adjuvants, the A/Vietnam/1203/2004 (H5N1) (Sanofi Pasteur), and the 2011 trivalent influenza vaccine (TIV) (Fluzone; Sanofi Pasteur) were received through the Office of Biomedical Advanced Research and Development Authority. The H7N9 vaccine was a split-virion vaccine derived from A/Shanghai/2/2013 (H7N9) virus, manufactured by Sanofi Pasteur, the same lot used for the clinical trials (NCT 01942265 and 01938742).
Viruses and Cells
The virus A/Anhui/1/2013 (H7N9) was used for the ferret challenge experiment and is antigenically similar to the vaccine strain [10] . The reverse-genetics (rg)-derived, attenuated virus strains used for serological assays were generated with the hemagglutinin (HA) and neuraminidase (NA) from A/Anhui/1/2013 and with the 6 internal genes from A/Puerto Rico/8/1934 (PR8).
Virus stocks was prepared by propagation in 10-day-old embryonated chicken eggs at 35°C for 36 hours, aliquoted, and stored at −70°C. Marin-Darby canine kidney cells used for virus titration were propagated in minimal essential medium supplemented with 10% fetal calf serum, vitamins, L-glutamine, and antibiotics in a humidified 5% carbon dioxide environment.
Immunization and Challenge
Specific-pathogen-free male ferrets, 4-6 months old, were purchased from Triple F Farms. Ferrets in 3 groups (6 per group) received 3.75, 15, or 45 µg of unadjuvanted vaccine, and ferrets in another 4 groups received 3.75 or 15 µg of vaccine adjuvanted with MF59 or AS03. Doses were calculated based on the HA concentration, as specified by the manufacturer. Vaccine was diluted in saline to the desired dose and mixed 1:1 with the adjuvant. A control group received saline only. All ferrets received 2 doses of vaccine, 3 weeks apart and administered in 0.5 mL volume, by intramuscular injection. Serum samples were collected at 21 and 16 days after the first and second doses respectively.
The challenge experiment was performed 19 days after the second dose. Ferrets were anesthetized with isoflurane and inoculated intranasally with 1 mL of 10 5 egg-infectious dose-50 (EID 50 ) of wild-type A/Anhui/1/2013 (H7N9) virus. Signs of infection, weight, and temperature were monitored for up to 12 days after the challenge. All animal experiments were performed according guidelines approved by the Institutional Animal Care and Use Committee in an enhanced animal biosafety level 3+ containment facility.
Nasal Wash and Tissue Samples
On days 3, 5, and 7 after virus inoculation, ferrets were anesthesized with ketamine, and nasal wash samples were collected in 1 mL of phosphate-buffered saline (PBS). On day 5 after inoculation, 3 ferrets from each group were euthanized, and lung tissues were collected from each lobe, pooled, and titrated on Marin-Darby canine kidney cells. After 3 days, a HA assay was performed and the virus titer was determined using the Reed and Muench method [11] . The limit of virus detection was <1 log 10 tissue culture infectious dose-50 per milliliter.
Serologic Assays
Serum samples were treated with receptor-destroying enzyme (Denka Seiken), heat inactivated at 56°C for 30 minutes, and tested in an hemagglutination inhibition (HI) assay with 0.5% chicken red blood cells [12] . Virus neutralization (VN) assays were performed according to World Health Organization guidelines [13] . To test the cross-reactivity of the ferret serum samples, β-propiolactone (BPL)-inactivated viruses were used in the HI assay. BPL inactivation was performed by adding 0.1% (vol/vol) of BPL to egg-grown virus stock and incubated at 4°C for 3 days before storage. NA-specific antibodies were determined using the enzymelinked lectin assay, as described elsewhere [14] . Recombinant rg-H6N9 virus comprising the NA from A/Anhui/1/2013 and a mismatched HA from A/Teal/Hong Kong/W312/1997 (H6N1) was used as antigen. Serum samples were tested at a starting dilution of 1:20.
Enzyme-Linked Immunosorbent Assay
Plates were coated overnight with 0.1 µg/mL of vaccine as antigen. Negative control wells were coated with buffer only. Plates were washed 3 times with PBS containing 0.05% Tween-20, blocked and added with serially diluted samples (starting at 1:200) for 2 hours at 37°C. Plates were washed and incubated with horseradish peroxidase-conjugated ferret immunoglobulin (Ig) G (Novus Biologicals) before reaction was developed with 3,3′,5,5′-tetramethylbenzidine substrate. Absorbance was read at 450 nm, and the last serum dilution that gave a positive/negative optical density readout ratio of >2 was determined as the end-point titer. 
SDS-PAGE Analysis
Vaccine (1 µg) was added to Laemmli buffer (250 mmol/L Trishydrochloride, 10% SDS, 30% glycerol, 5% β-mercaptoethanol, and 0.02% bromophenol blue) and boiled (denatured) for 5 minutes. In the native preparation, the β-mercaptoethanol and boiling were omitted. Samples were electrophoresed on a 4%-15% gradient SDS-PAGE gel and transferred onto a nitrocellulose membrane. Membranes were probed with mouse monoclonal antibodies against influenza A H1 (monoclonal antibody CA09-9; gift from Elena Govorkova, St Jude Children's Research Hospital), H5 (clone 8D2; Abcam), or H7 (clone 1H11; Abcam; derived from A/seal/Massachusetts/1980 [H7N7]), followed by anti-mouse IgG-horseradish peroxidase conjugate (Cell Signaling) and developed with enhanced chemiluminescent substrate.
Transmission Electron Microscopy
3 µL of sample was deposited on a thin carbon film supported on a Holey Formvar grid and allowed to stand for 3 minutes. 3 µL of 2% phosphotungstic acid or 1% uranyl acetate was added to negatively stain the sample for 1 minute. Air-dried samples were subjected to image acquisition at 80 or 200 kV with an FEI TF20 transmission electron microscope.
Statistical Tests
Data were analyzed using software from GraphPad Prism (version 5.03) and SAS (version 9.3). Antibody titers were expressed as geometric mean titers (GMTs) with upper and lower 95% confidence intervals (CIs), and viral titers as mean titers with standard deviations (expressed as log 10 tissue culture infectious dose per milliliter or per gram tissue). Vaccine immunogenicity was compared using log 10 -transformed antibody titers with analysis of variance. Bonferroni corrections were made for multiple comparisons. Antibody titers measured with the different assays were correlated using untransformed titers by calculating the Spearman correlation coefficient (r s ).
The antibody correlate for protection (defined as 50% reduction of total virus shed or 50% inhibitory concentration [IC 50 ]) was determined from nonlinear regression (4-parameter model, with variable slope function) of log-transformed antibody titers and total virus load, expressed as the area under the curve (AUC) from a virus shedding curve. To obtain the IC 50 , AUC values were normalized to percentages, with the minimum AUC (baseline) set to 0% and maximum AUC defined as the mean AUC of saline control group, set at 100%. Linear mixed model with Kenward-Roger corrections were applied to investigate log 10 -transformed viral titers across various treatment groups for the virus challenge study. A weighted Fisher exact test was applied to evaluate cross-reactivity. Differences were considered statistically significant at P ≤ .05.
RESULTS
Immunogenicity of Unadjuvanted, MF59 and AS03-adjuvanted H7N9 Vaccine in Ferrets
To assess the immunogenicity of the different vaccine formulation, we measured the serum antibody responses against HA (by HI) and NA (by enzyme-linked lectin assay) as well as by VN assay and ELISA. All unadjuvanted vaccines failed to induce detectable HI titer even after 2 doses (Table 1 ). In contrast, Abbreviations: CI, confidence interval; GMT, geometric mean titer; HI, hemagglutination inhibition; VN, virus neutralization. a There were 6 ferrets per group. Titers <20 were arbitrarily set at 5. Statistical significance was determined by analysis of variance using log-transformed antibody titer, with Bonferroni adjustment for multiple comparisons. with the exception of the 3.75-µg, MF59-adjuvanted group, most ferrets that received adjuvanted vaccines developed HI titers ≥40 (considered protective based on human seasonal influenza vaccine studies in adults [15] ) after 1 dose. After boosting, however, almost all ferrets in the adjuvanted vaccine groups had HI titers ≥40. A single dose at 3.75 µg adjuvanted with AS03 was able to induce an antibody titer of ≥40 in all the ferrets (GMT, 71.3; 95% CI, 34.9-145.7), compared with only 1 ferret in the MF59-adjuvanted group (6 of 6 vs 1 of 6; P = .02). After 2 doses, AS03-adjuvanted vaccines induced a 20-fold difference compared with MF59 in the 3.75-µg group (P < .001). However, with the 15-µg groups, the difference was not statistically significant. HI assay performed with horse red blood cells showed similar trends (Supplementary Table 2 ). Because neutralization assays have greater sensitivity in detecting antibodies against avian influenza viruses [16] [17] [18] , we tested the serum samples in a VN assay. The VN assay was more sensitive than the HI assay (Table 1) in detecting influenza antibodies, a difference that was most evident in the lower titer range. VN antibodies at titers >40 were detected in some ferrets that did not show HI titers ≥40 in the unadjuvanted vaccine and 3.75-µg, MF59 groups. Overall, after 2 doses of vaccines, VN titers correlated strongly with HI titers (r s = 0.92; P < .001) (Supplementary Figure 1A) . This statistical significance was weaker when analysis was stratified to individual groups, probably owing to the smaller sample size. No meaningful correlations were detected for the unadjuvanted group because they had low or no detectable titers.
Adjuvanted vaccines also stimulated robust NA-inhibiting (NI) titers after 2 doses (GMT, 200-1796), compared with unadjuvanted vaccines (GMT, 7-13) ( Table 2 ). AS03 induced approximately 4-5-fold higher NI titer compared with MF59 at the same doses, but this difference was not statistically significant. Overall, after 2 doses, there was a strong correlation between NI titers with VN (r s = 0.88; P < .001) (Supplementary Figure 1B) and HI (r s = 0.87; P < .001) (Supplementary Figure 1C) titers, suggesting that there is a concurrent induction of HA and NA antibodies that is associated with VN activities. When results were stratified by the individual vaccine group, significant HI-NI titer correlation was observed only in the MF59-adjuvanted 3.75-µg group (r s = 0.82; P = .06). Notably in the AS03-adjuvanted 15-µg group, there seemed a trend toward an inverse correlation between HI-NI titer (r s = −0.71; P = .13), and VN-NI titers (r s = −0.66; P = .18).
To determine whether the low titers detected in the unadjuvanted group were due to poor immunogenicity of the H7N9 vaccine or selective failure to induce functional antibodies, we measured total HA-specific IgG in serum samples. After 2 doses, unadjuvanted vaccine groups did not produce significantly higher titers compared with the saline group (Table 3) . In contrast, all ferrets that received adjuvanted vaccines showed at least 50-100-fold higher influenza HA-specific IgG titer (mean GMT, 11 404-25 600). There was also a significant correlation between HA-specific IgG-titers and VN titers (r s = 0.91; P < .001) overall, but no significant correlation was detected with stratification by individual vaccine groups (Supplementary Figure 1D) . Taken together, the H7N9 vaccine was poorly immunogenic overall, generating low antigen-specific antibody responses.
Protection Against Virus Challenge
To evaluate the protective efficacy of the vaccines, we subsequently challenged the ferrets with 10 5 EID 50 of the wild-type A/Anhui/1/3013 (H7N9) virus. At challenge, no overt symptoms were observed in any ferrets although, inexplicably, ferrets in the 45-µg group seemed to lose more weight than the salinetreated group (Supplementary Figure 2) . With the exception of the 3.75-µg, MF59 group, ferrets in the adjuvanted vaccine groups shed less virus in the nasal wash samples than did the unadjuvanted and saline groups on days 3 and 5 ( Figure 1 ) (.0003 ≤ P < .05). There was an earlier viral clearance in all ferrets in the adjuvanted vaccine and the 45-µg groups but not in the saline and unadjuvanted 3.75-µg and 15-µg groups. There was a trend toward reduced viral shedding in the AS03 group compared with the MF59 group, but this difference was not statistically significant. In the lungs, 1 ferret each in the saline control and 45-µg groups and 2 ferrets in the 15-µg group had detectable virus titer; no ferrets in the unadjuvanted 3.75-µg and the adjuvanted vaccine groups had detectable virus titers in the lungs (Supplementary Table 1 ).
Correlate of Protection
To obtain a measure of correlate of protection based on antibody titers in the ferret model, we performed nonlinear regression of serum HI, VN, NA, and HA-IgG titer with the cumulative viral load shed by the individual ferrets. large CI for the IC 50 for NI, and HA-IgG titers suggests that these assays may not be as robust in predicting infection outcome.
Cross-reactivity of the H7N9 Vaccine
To test the cross-reactivity of the antibodies, we tested the serum samples after 2 doses in an HI assay against 2 H7 strains that have caused human infections, that is, H7N7 (A/Netherlands/219/03), and H7N3 (rg-A/Canada/rv444/04). Two prototypical H7 strains, A/equine/Prague/2/56 (H7N7) and A/ruddy turnstone/ New Jersey/65/85 (H7N3), were included as references. Netherlands/219, equine/Prague, and the H7N9 viruses represent the Eurasian genetic lineage, which are genetically and antigenically dissimilar from the North American lineage viruses (Canada/ rv444 and ruddy turnstone/NJ) (Supplementary Table 3 ). The unadjuvanted vaccine group did not have detectable HI titer to any of the viruses tested (data not shown), and ferrets in the 3.75-µg, MF59-adjuvanted group showed no or low crossreactive activity. HI titers were detected in ferrets that mounted a robust homologous HI antibody response (Table 4) . Titers were higher against Netherlands/219 (H7N7) than against Canada/ rv444 (H7N3) in the 15-µg, MF59-adjuvanted group (P < .01). Interestingly, despite the higher homologous GMT in the AS03, 15-µg group, the magnitude, number of seropositive ferrets, and breadth of cross-reactivity were lower than in the lower-dose (3.75-µg) group (P < .001). This observation was still valid even after the high-responder ferret, ARC12, was excluded from analysis (P < .001).
In Vitro Correlate of Immunogenicity
To better understand the in vitro correlates of immunogenicity, we undertook an investigation similar to that done by Couch et al [9] , comparing the current H7N9 vaccine with the human seasonal and the H5N1 vaccines. We used ELISAs and Western blot analyses with native and denatured vaccine preparations to evaluate the integrity of the vaccine epitopes ( Figure 3A) . With ELISAs, reactivity was higher with native vaccine in both ferret polyclonal serum samples and monoclonal antibodies for all 3 vaccines. In a Coomasie-stained gel, bands corresponding to sizes of nucleoprotein, HA-monomer (75 kDa), and larger protein complexes were visible in the native samples for TIV and H7 (150-250 kDa) ( Figure 3B ), but not the H5 vaccine. In the Western blot analysis, blot bands were detected in the native lanes at high molecular weights corresponding to HA trimer, dimer, and monomers in all 3 vaccines ( Figure 3B ). Cleaved HA bands were also detected for TIV and H5 vaccine under nonreduced conditions (data not shown). A band corresponding to HA-monomer was detected in denatured samples in the TIV and H5 samples but not in the denatured H7 samples. This could likely due to the mismatched H7 monoclonal antibody used as the primary detection antibody. These results suggest that the H7N9 vaccine contained HA complexes with intact immune epitopes. Figure 2 . Relationship between hemagglutination inhibition (HI) (A), virus neutralization (VN) (B), neuraminidase (NA) (C), and hemagglutinin (HA)-immunoglobulin (Ig) G antibody (D) titers with total viral load. The x-axes represent log-transformed antibody titers; the y-axes, the area under the curve (AUC) of a viral shedding curve as a measure of cumulative viral load throughout the study period. The AUC values here have been normalized to a percentage, with the minimum and maximum AUCs set to 0% and 100%, respectively. The R 2 value indicates the goodness of fit, and the antibody titer that correlates to 50% reduction in total viral load is expressed as the 50% inhibitory concentration (IC 50 ). Abbreviation: CI, confidence interval.
Electron micrographs showed that all 3 vaccines contained numerous small, punctate structures (10-30 nm; yellow arrowheads in Figure 3C ), which tended to aggregate in the H5 vaccine (white arrowhead). Larger spherical structures with glycoproteinlike projections, corresponding to those described by Couch et al [9] as intact or split-virus particles, were observed with H7N9 and TIV vaccine preparations but were mostly absent with the H5N1 preparation.
DISCUSSION
The results of a phase II trial (NTC01938742) of the same H7N9 vaccine used in our study were published in 2014 [19] . Our findings mirrors the clinical findings in 2 ways: (1) adjuvanted vaccines induced more robust antibody titers than unadjuvanted vaccines and (2) neutralization titers were generally 2-3-fold higher than HI titers. In contrast to our results, Mulligan et al [19] did not see improved antibody titers with increasing HA dose beyond the 3.75-µg HA-MF59 adjuvanted dose. Although this is speculative, perhaps the saturated response is due to the interaction with preexisting immunity to seasonal influenza in adult humans, as reported in that study [19] , compared with the naive ferrets that we used. In some situations however, antigen dose can influence immunogenicity, as was observed in the MF59-adjuvanted H5N1 clinical trial [20] . Adjuvant use has circumvented the issue of poor immunogenicity for influenza vaccines in many situations [21] [22] [23] [24] [25] . Both MF59 and AS03 are squalene-based emulsions that act by stimulating a local inflammatory environment, and by promoting the recruitment and activation of immune cells. AS03 has an added component of α-tocopherol (vitamin E), an immunostimulant [26] that was important for its potent adjuvant effect [27] . Despite the better immunogenicity of AS03-adjuvanted vaccines, α-tocopherol can also be associated with higher reactogenicity. Thus, recent formulations of AS03 with less α-tocopherol have shown a better reactogenicity-immunogenicity balance [28, 29] . In our study, when AS03 was administered to ferrets in equivalent doses, we found that it was more potent than MF59, because it raised higher antibody titers at a lower antigen dose. However, at a 15-µg dose, there were essentially no differences between the adjuvants. Because Focetria and Pandemrix (MF59-and AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccines, licensed for use in Europe), are , and H5N1 vaccines. The blot was allowed to be overexposed to visualize the less abundant hemagglutinin (HA) monomer in the reduced samples. C, Electron micrograph of the vaccines. Small spherical structures (arrowheads) and large spherical structures with glycoproteinlike projections emanating from the convex face (asterisks) are seen. Images were captured at ×29 000 magnification for TIV and H7N9 and ×50 000 magnifications for H5N1 vaccines. Abbreviations: NP, nucleoprotein; OD, optical density. formulated in 7.5-and 3.75-µg doses, respectively, we expect that the eventual MF59-adjuvanted H7N9 vaccine will be formulated with a higher dose of HA than AS03, and will thus be likely to show comparable immunogenicity.
In our study, ferrets that had a robust antibody response also mounted cross-reactive antibodies to other H7 strains. This may already be sufficient to protect against heterologous H7 virus infection, [30] or prime the adaptive immune arm against subsequent H7 virus infections. Interestingly, with an increased antigen dose, AS03 seemed to have a more HA-dominant and specific antibody repertoire, as evidenced by the inverse correlation in HI-NI titer and limited cross-reactive titers. Because the availability of antigen can influence the resulting antibody repertoire in an adjuvanted vaccine response [31] , it is likely that the higher abundance of HA may have dominated and perhaps even narrowed the specificity of the antibody response.
Although VN assays were more sensitive than HI assays, HI titers were a better antibody correlate of protection, at least in the ferret model. Based on the predicted IC 50 , a single dose of AS03-adjuvanted vaccine at 15 µg may already be sufficient to reduce the viral load by 50% in the ferret. Nevertheless, though this correlate of protection is in the context of the ferret model and does not represent a similar correlate in humans, it does demonstrate that antibody-mediated protection is real. This protection is also not due to nonspecific effects mediated by the adjuvants since immunization with the adjuvants alone has been shown not to impact viral burden [32] . Although preexisting HI titers were well correlated to reduced viral load, the absence of an HI titer does not preclude the absence of protection. Observations from other studies [33, 34] , as well as our own finding of early viral clearance in the unadjuvanted 45-µg group, suggest that other immune mechanism, such as cellular immunity, may be important in limiting virus infection after vaccination.
A limitation to our study is that we were unable to determine the vaccine's effects in preventing infection in the lungs because we observed inconsistent results in the lung viral titers. Although the replication is efficient in the upper respiratory tract, replication in the lungs is less uniformly achieved with H7N9 in the ferret model [35] [36] [37] [38] [39] .
In conclusion, we find that adjuvanted H7N9 vaccines stimulated robust antibody response and decreased the viral load in infected ferrets. Given the dismal performance of unadjuvanted formulations in human clinical trials [4, 5, 40] , we believe that adjuvanted H7N9 vaccine would be sufficiently immunogenic and able to reduce the H7N9 disease burden in humans.
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